Completed PHASE1 INTERVENTIONAL 3-arm NCT07044401

A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices

A Phase 1, Randomized, Open-label, Single-Dose, Crossover Study to Investigate the Effect of Injection Site on Relative Bioavailability of KAI-9531 Subcutaneous Injection in Participants With a Range of Body Mass Indices

Sponsor: Kailera

Conditions Healthy Volunteers

Interventions KAI-9531

Updated 3 times since 2025 Last updated: Dec 4, 2025 Started: Jul 14, 2025 Primary completion: Nov 13, 2025 Completion: Nov 13, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07044401, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by Kailera, it has been updated 3 times since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Sep 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE1

Status: Not Yet Recruiting → Active Not Recruiting
Aug 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE1

First recorded

Jul 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kailera

Data source: Kailera

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tempe, United States